Stay updated with breaking news from Treatment Patterns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH)...
estrogen-receptor-negative HER2-negative This means that the growth of the cancer isn’t driven by the hormones estrogen or progesterone, or by the HER2 protein. So, triple-negative breast cancer doesn’t respond to hormonal therapy medicines or medicines that target HER2 protein receptors. About 15% of breast cancers are triple-negative. Triple-negative breast cancers tend to be: considered more aggressive than hormone-receptor-positive or HER2-positive breast cancer, mainly because there are few targeted therapy medicines that treat triple-negative breast cancer; studies suggest that trip...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy ... Helsinn Healthcare S.A.February 18, 2021 GMT Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical...